Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma

Journal of Cutaneous Pathology

Volumn 33, Issue 12, 2006, Pages 793-798

  Pantanowitz, Liron ^a,d   Dezube, Bruce J ^b   Hernandez Barrantes, Sonia ^c   Tahan, Steven R ^b   Dabbous, Mustafa K ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; COLLAGENASE 3; DOXORUBICIN; GELATINASE A; GELATINASE B; IMATINIB; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MONOCLONAL ANTIBODY; STROMELYSIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INFLAMMATORY CELL; KAPOSI SARCOMA; MACROPHAGE; MALE; MULTIPLE CYCLE TREATMENT; SYSTEMIC THERAPY; TISSUE SECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; SARCOMA, KAPOSI;

EID: 33845566461     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00567.x     Document Type: Article

References (24)

1. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178.
2. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43 (Suppl.): S42.
3. Dezube BJ. The role of HIV-1 in the pathogenesis of AIDS-related Kaposi's sarcoma: the importance of an inflammatory and angiogenic milieu. Semin Oncol 2000; 27: 420.
4. Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol 2004; 16: 443.
5. Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 1994; 6: 251.
6. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. The Oncologist 2005.
7. Pfeffer U, Bisacchi D, Morini M, et al. Human chorionic gonadotropin inhibits Kaposi's sarcoma associated angiogenesis, matrix metalloprotease activity, and tumor growth. Endocrinology 2002; 143: 3114.
8. Meade-Tollin LC, Way D, Witte MH. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 1999; 101: 305.
9. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001; 12: 2934.
10. Pantanowitz L, Dezube BJ, Pinkus GS, Tahan SR. Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol 2004; 31: 26.
11. Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment. AIDS Read 2004; 14: 236.
12. Fingleton B, Matrisian LM. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol 2001; 13: 368.
13. Albini A, Fontanini G, Masiello L, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994; 8: 1237.
14. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20: 153.
15. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004; 6: 96.
16. Impola U, Cuccuru MA, Masala MV, et al. Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol 2003; 149: 905.
17. Blankaert D, Simonart T, Van Vooren JP, et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 203.
18. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225.
19. Roebuck MM, Helliwell TR, Ritchie DA, et al. Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 2005; 123: 405.
20. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004; 31 (Suppl. 13): 36.
21. Koon HB, Bubley GJ, Pantonowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23: 982.
22. Albini A, Morini M, D'Agostini F, et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 2001; 61: 8171.
23. Dabbous MK, Wooley DE, Haney L, Carter LM, Nicolson GL. Host-mediated effectors of tumor invasion. Clin Exp Metastasis 1986; 4: 141.
24. Dabbous MK, North SM, Haney L, Nicolson GL. Macrophage and lymphocyte potentiation of syngeneic tumor cell and host fibroblast collagenolytic activity. Cancer Res 1988; 48: 6832.